OPRX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

30.91M

-4.34%

0.224

-25.24%

23.03M

+5.01%

0.043

-45.84%

28.14M

-3.6%

0.155

-35.42%

Estimates Revision

The market is revising Upward the revenue expectations for OptimizeRx Corporation (OPRX) for FY2025, with the revenue forecasts being adjusted by 1.57% over the past three months. During the same period, the stock price has changed by -28.18%.

Revenue Estimates for FY2025

Revise Upward

+1.57%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+14.72%

In Past 3 Month

Stock Price

Go Down

-28.18%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast OPRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPRX is 24.97 USD with a low forecast of 17.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 12.770

Low

17.00

Averages

24.97

High

32.00

Current: 12.770

Low

17.00

Averages

24.97

High

32.00

Stephens

Jeff Garro

Equal Weight

downgrade

$20 -> $17

2025-11-17

Reason

Stephens

Jeff Garro

Price Target

$20 -> $17

2025-11-17

downgrade

Equal Weight

Reason

Stephens analyst Jeff Garro lowered the firm's price target on OptimizeRx to $17 from $20 and keeps an Equal Weight rating on the shares. Noting that shares are up greater than 200% year-to-date, the firm views the current risk/reward as balanced and looks to confirm business momentum exceeding conservative pipeline assumptions.

B. Riley

Buy

upgrade

$18 -> $28

2025-11-07

Reason

B. Riley

Price Target

$18 -> $28

2025-11-07

upgrade

Buy

Reason

B. Riley raised the firm's price target on OptimizeRx to $28 from $18 and keeps a Buy rating on the shares. The firm views the company's Q3 report as strong.

Lake Street

Buy

maintain

$20 -> $24

2025-11-07

Reason

Lake Street

Price Target

$20 -> $24

2025-11-07

maintain

Buy

Reason

Lake Street raised the firm's price target on OptimizeRx to $24 from $20 and keeps a Buy rating on the shares, telling investors that the firm was "pleased" with the company's third consecutive strong quarter and guide. The FY26 revenue midpoint equates to growth of 13%, which compares favorably to the 11% consensus, the analyst noted.

Roth Capital

Buy

upgrade

$27 -> $32

2025-11-07

Reason

Roth Capital

Price Target

$27 -> $32

2025-11-07

upgrade

Buy

Reason

Roth Capital raised the firm's price target on OptimizeRx to $32 from $27 and keeps a Buy rating on the shares. The company reported strong Q3 results and beat its guidance again, while its visibility is clearly much improved after 2024's weak execution, the analyst tells investors in a research note.

Stifel

David Grossman

Buy

maintain

$18 -> $21

2025-11-07

Reason

Stifel

David Grossman

Price Target

$18 -> $21

2025-11-07

maintain

Buy

Reason

Stifel analyst David Grossman raised the firm's price target on OptimizeRx to $21 from $18 and keeps a Buy rating on the shares. Revenue for the quarter materially outperformed, which drove significant EPS outperformance, the analyst tells investors in a research note. The firm added that it believes there's a foundation for ongoing double-digit growth and expanding margins.

Citizens JMP

Constantine Davides

Outperform

maintain

$23 -> $24

2025-11-07

Reason

Citizens JMP

Constantine Davides

Price Target

$23 -> $24

2025-11-07

maintain

Outperform

Reason

Citizens JMP analyst Constantine Davides raised the firm's price target on OptimizeRx to $24 from $23 and keeps an Outperform rating on the shares. OptimizeRx showed continuing momentum in Q3 and established formal guidance for 2026, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for OptimizeRx Corp (OPRX.O) is 18.09, compared to its 5-year average forward P/E of 60.36. For a more detailed relative valuation and DCF analysis to assess OptimizeRx Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

60.36

Current PE

18.09

Overvalued PE

98.14

Undervalued PE

22.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

54.80

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

102.32

Undervalued EV/EBITDA

7.29

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

5.99

Current PS

0.00

Overvalued PS

11.50

Undervalued PS

0.49

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

OPRX News & Events

Events Timeline

No data

News

7.5

10:21 AMGlobenewswire

OptimizeRx Expands POC Network with Four New Partner Agreements, Increasing NPI Reach by 37%

7.5

10:13 AMNewsfilter

OptimizeRx Expands NPI Reach by 37% with Four New Partner Agreements

3.5

12-11Globenewswire

Ophirex Secures FDA Agreement for Varespladib Snakebite Treatment Development

People Also Watch

Frequently Asked Questions

What is OptimizeRx Corp (OPRX) stock price today?

The current price of OPRX is 12.77 USD — it has decreased -3.11 % in the last trading day.

What is OptimizeRx Corp (OPRX)'s business?

OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.

What is the price predicton of OPRX Stock?

What is OptimizeRx Corp (OPRX)'s revenue for the last quarter?

OptimizeRx Corp revenue for the last quarter amounts to 26.07M USD, increased 22.33 % YoY.

What is OptimizeRx Corp (OPRX)'s earnings per share (EPS) for the last quarter?

OptimizeRx Corp. EPS for the last quarter amounts to 0.04 USD, decreased -108.00 % YoY.

What changes have occurred in the market's expectations for OptimizeRx Corp (OPRX)'s fundamentals?

How many employees does OptimizeRx Corp (OPRX). have?

OptimizeRx Corp (OPRX) has 106 emplpoyees as of December 17 2025.

What is OptimizeRx Corp (OPRX) market cap?

Today OPRX has the market capitalization of 238.04M USD.